{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T10:36:23Z","timestamp":1790764583991,"version":"4.1.0"},"reference-count":32,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2021,1,16]],"date-time":"2021-01-16T00:00:00Z","timestamp":1610755200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["T32-AI052071"],"award-info":[{"award-number":["T32-AI052071"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,5,28]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Antibiotic-associated adverse events (AEs) in hospitalized children have not been comprehensively characterized.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a retrospective observational study of children hospitalized at The Johns Hopkins Hospital receiving \u226524 hours of systemic antibiotics. Consensus regarding antibiotic-associated AE definitions was established by 5 infectious diseases specialists prior to data collection. Two physicians reviewed potential AEs and determined whether they were more likely than not related to antibiotics after comprehensive manual chart review. Inpatient and post-discharge AEs were identified using the Epic Care Everywhere network. AEs evaluated from the initiation of antibiotics until 30 days after antibiotic completion included gastrointestinal, hematologic, hepatobiliary, renal, neurologic, dermatologic, cardiac, myositis, vascular access device-related events, and systemic reactions. Ninety-day AEs included Clostridioides difficile infections, multidrug-resistant organism infections, and clinically significant candidal infections. The impact of AEs was categorized as necessitating additional diagnostic testing, changes in medications, unplanned medical encounters, prolonged or new hospitalizations, or death.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 400 antibiotic courses, 21% were complicated by at least one AE and 30% occurred post-discharge. Each additional day of antibiotics was associated with a 7% increased odds of an AE. Of courses complicated by an AE, 66% required further intervention. Hematologic, gastrointestinal, and renal AEs were the most common, accounting for 31%, 15%, and 11% of AEs, respectively. AEs complicated 35%, 35%, 19%, and 18% of courses of piperacillin-tazobactam, tobramycin, ceftazidime, and vancomycin, respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>More than 1 in 5 courses of antibiotics administered to hospitalized children are complicated by AEs. Clinicians should weigh the risk of harm against expected benefit when prescribing antibiotics.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jpids\/piaa173","type":"journal-article","created":{"date-parts":[[2020,12,23]],"date-time":"2020-12-23T15:32:58Z","timestamp":1608737578000},"page":"622-628","source":"Crossref","is-referenced-by-count":48,"title":["Antibiotic-Associated Adverse Events in Hospitalized Children"],"prefix":"10.1093","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0337-1168","authenticated-orcid":false,"given":"Rebecca G","family":"Same","sequence":"first","affiliation":[{"name":"Department of Pediatrics, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice J","family":"Hsu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The Johns Hopkins Hospital, Baltimore, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9458-4331","authenticated-orcid":false,"given":"Sara E","family":"Cosgrove","sequence":"additional","affiliation":[{"name":"Department of Medicine, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eili Y","family":"Klein","sequence":"additional","affiliation":[{"name":"Department of Emergency Medicine, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joe","family":"Amoah","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam L","family":"Hersh","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University of Utah, Salt Lake City, Utah, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew P","family":"Kronman","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University of Washington, Seattle, Washington, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4143-6324","authenticated-orcid":false,"given":"Pranita D","family":"Tamma","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,1,16]]},"reference":[{"issue":"5","key":"2021052817051746800_CIT0001","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1017\/ice.2019.373","article-title":"Considerable variability in antibiotic use among US children\u2019s hospitals in 2017\u20132018","volume":"41","author":"Griffith","year":"2020","journal-title":"Infect Control Hosp Epidemiol"},{"key":"2021052817051746800_CIT0002","doi-asserted-by":"crossref","first-page":"e226","DOI":"10.1093\/cid\/ciaa036","article-title":"Appropriateness of antibiotic prescribing in United States children\u2019s hospitals: a national point prevalence survey","volume":"71","author":"Tribble","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2021052817051746800_CIT0003","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1542\/peds.2010-1275","article-title":"Variability in antibiotic use at children\u2019s hospitals","volume":"126","author":"Gerber","year":"2010","journal-title":"Pediatrics"},{"key":"2021052817051746800_CIT0004","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1001\/jamainternmed.2017.1938","article-title":"Association of adverse events with antibiotic use in hospitalized patients","volume":"177","author":"Tamma","year":"2017","journal-title":"JAMA Intern Med"},{"issue":"5","key":"2021052817051746800_CIT0005","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1093\/jpids\/piy066","article-title":"US emergency department visits for adverse drug events from antibiotics in children, 2011\u20132015","volume":"8","author":"Lovegrove","year":"2019","journal-title":"J Pediatric Infect Dis Soc"},{"key":"2021052817051746800_CIT0006","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1542\/peds.2005-2429","article-title":"Adverse drug reactions among children over a 10-year period","volume":"118","author":"Le","year":"2006","journal-title":"Pediatrics"},{"key":"2021052817051746800_CIT0007","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1007\/s40264-019-00856-9","article-title":"Prevalence and nature of medication errors and preventable adverse drug events in paediatric and neonatal intensive care settings: a systematic review","volume":"42","author":"Alghamdi","year":"2019","journal-title":"Drug Saf"},{"key":"2021052817051746800_CIT0008","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1093\/jpids\/piz053","article-title":"Use of antimicrobial agents in hospitalized children for noninfectious indications","volume":"9","author":"Jaggi","year":"2020","journal-title":"J Pediatric Infect Dis Soc"},{"key":"2021052817051746800_CIT0009"},{"key":"2021052817051746800_CIT0010","first-page":"1","article-title":"Kidney disease: improving global outcomes (KDIGO) acute kidney injury work group. KDIGO clinical practice guideline for acute kidney injury","volume":"2","year":"2012","journal-title":"Kidney Int Suppl"},{"key":"2021052817051746800_CIT0011","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1186\/1471-2334-11-194","article-title":"Incidence of and risk factors for community-associated Clostridium difficile infection: a nested case-control study","volume":"11","author":"Kuntz","year":"2011","journal-title":"BMC Infect Dis"},{"key":"2021052817051746800_CIT0012","doi-asserted-by":"crossref","first-page":"e01440","DOI":"10.1128\/AAC.01440-17","article-title":"Multicenter study of the risk factors for colonization or infection with carbapenem-resistant Enterobacteriaceae in children","volume":"61","author":"Chiotos","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2021052817051746800_CIT0013","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1080\/23744235.2019.1654127","article-title":"Risk factors for community acquired urinary tract infections caused by extended spectrum \u03b2-lactamase (ESBL) producing Escherichia coli in children: a case control study","volume":"51","author":"Zhu","year":"2019","journal-title":"Infect Dis (Lond)"},{"key":"2021052817051746800_CIT0014","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1093\/jpids\/pix096","article-title":"Cost and potential avoidability of antibiotic-associated adverse drug reactions in children","volume":"8","author":"Beck","year":"2019","journal-title":"J Pediatric Infect Dis Soc"},{"key":"2021052817051746800_CIT0015","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1080\/14740338.2019.1640678","article-title":"Antibiotic-related adverse events in paediatrics: unique characteristics","volume":"18","author":"Principi","year":"2019","journal-title":"Expert Opin Drug Saf"},{"key":"2021052817051746800_CIT0016","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1136\/archdischild-2019-317950","article-title":"Safety of ceftriaxone in paediatrics: a systematic review","volume":"105","author":"Zeng","year":"2020","journal-title":"Arch Dis Child"},{"key":"2021052817051746800_CIT0017","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1136\/adc.2010.208843","article-title":"Ciprofloxacin safety in paediatrics: a systematic review","volume":"96","author":"Adefurin","year":"2011","journal-title":"Arch Dis Child"},{"key":"2021052817051746800_CIT0018","doi-asserted-by":"crossref","first-page":"e239","DOI":"10.1097\/INF.0000000000001191","article-title":"A multicenter, randomized, observer-blinded, active-controlled study to evaluate the safety and efficacy of ceftaroline versus comparator in pediatric patients with acute bacterial skin and skin structure infection","volume":"35","author":"Korczowski","year":"2016","journal-title":"Pediatr Infect Dis J"},{"key":"2021052817051746800_CIT0019","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s40121-016-0144-8","article-title":"Use of ceftaroline fosamil in children: review of current knowledge and its application","volume":"6","author":"Yim","year":"2017","journal-title":"Infect Dis Ther"},{"key":"2021052817051746800_CIT0020","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1093\/jpids\/piy030","article-title":"Incidence of nephrotoxicity among pediatric patients receiving vancomycin with either piperacillin-tazobactam or cefepime: a cohort study","volume":"8","author":"Cook","year":"2019","journal-title":"J Pediatric Infect Dis Soc"},{"key":"2021052817051746800_CIT0021","doi-asserted-by":"crossref","first-page":"e173219","DOI":"10.1001\/jamapediatrics.2017.3219","article-title":"Association of acute kidney injury with concomitant vancomycin and piperacillin\/tazobactam treatment among hospitalized children","volume":"171","author":"Downes","year":"2017","journal-title":"JAMA Pediatr"},{"key":"2021052817051746800_CIT0022","doi-asserted-by":"crossref","first-page":"e01572","DOI":"10.1128\/AAC.01572-19","article-title":"The association of acute kidney injury with the concomitant use of vancomycin and piperacillin\/tazobactam in children: a systematic review and meta-analysis","volume":"63","author":"Kalligeros","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"2021052817051746800_CIT0023","doi-asserted-by":"crossref","first-page":"e24061","DOI":"10.1371\/journal.pone.0024061","article-title":"Adverse drug reactions in children\u2013a systematic review","volume":"7","author":"Smyth","year":"2012","journal-title":"PLoS One"},{"key":"2021052817051746800_CIT0024","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.ajic.2004.12.004","article-title":"Assessing motivation for physicians to prevent antimicrobial resistance in hospitalized children using the Health Belief Model as a framework","volume":"33","author":"Brinsley","year":"2005","journal-title":"Am J Infect Control"},{"key":"2021052817051746800_CIT0025","doi-asserted-by":"crossref","first-page":"S69","DOI":"10.1086\/677826","article-title":"Pediatrician perceptions of an outpatient antimicrobial stewardship intervention","volume":"35","author":"Szymczak","year":"2014","journal-title":"Infect Control Hosp Epidemiol"},{"key":"2021052817051746800_CIT0026","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1093\/jpids\/pis045","article-title":"Clinicians\u2019 attitudes towards an antimicrobial stewardship program at a children\u2019s hospital","volume":"1","author":"Stach","year":"2012","journal-title":"J Pediatric Infect Dis Soc"},{"key":"2021052817051746800_CIT0027","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1017\/ice.2015.136","article-title":"Factors influencing antibiotic-prescribing decisions among inpatient physicians: a qualitative investigation","volume":"36","author":"Livorsi","year":"2015","journal-title":"Infect Control Hosp Epidemiol"},{"key":"2021052817051746800_CIT0028","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1017\/ice.2020.183","article-title":"Prescriber perceptions of fluoroquinolones, extended-spectrum cephalosporins, and Clostridioides difficile infection","volume":"41","author":"Szymczak","year":"2020","journal-title":"Infect Control Hosp Epidemiol"},{"key":"2021052817051746800_CIT0029","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1126\/science.aat4595","article-title":"Opioid prescribing decreases after learning of a patient\u2019s fatal overdose","volume":"361","author":"Doctor","year":"2018","journal-title":"Science"},{"key":"2021052817051746800_CIT0030","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1377\/hlthaff.2015.1025","article-title":"Medicare letters to curb overprescribing of controlled substances had no detectable effect on providers","volume":"35","author":"Sacarny","year":"2016","journal-title":"Health Aff (Millwood)"},{"key":"2021052817051746800_CIT0031","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1001\/jama.2017.18715","article-title":"Association of broad- vs narrow-spectrum antibiotics with treatment failure, adverse events, and quality of life in children with acute respiratory tract infections","volume":"318","author":"Gerber","year":"2017","journal-title":"JAMA"},{"key":"2021052817051746800_CIT0032","author":"Epic"}],"container-title":["Journal of the Pediatric Infectious Diseases Society"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jpids\/article-pdf\/10\/5\/622\/38360545\/piaa173.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jpids\/article-pdf\/10\/5\/622\/38360545\/piaa173.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,28]],"date-time":"2021-05-28T14:37:38Z","timestamp":1622212658000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jpids\/article\/10\/5\/622\/6102462"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,16]]},"references-count":32,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2021,1,16]]},"published-print":{"date-parts":[[2021,5,28]]}},"URL":"https:\/\/doi.org\/10.1093\/jpids\/piaa173","relation":{},"ISSN":["2048-7207"],"issn-type":[{"value":"2048-7207","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,5,1]]},"published":{"date-parts":[[2021,1,16]]}}}